TAYSHA GENE THERAPIES, INC.
Last · —$3.51-0.07 (-1.96%)live · yahoo · 1h ago
Market cap$1.14B—
P/E · TTM—fwd — · eps —
Beta—vs S&P 500
Div yield—annual · TTM
52w range
——
Volume—session
| Revenue | $9.8M |
|---|---|
| Operating income | $-110.5M |
| Net income | $-109.0M |
| Free cash flow | $-93.8M |
| Operating margin | -1130.6% |
| Net margin | -1115.3% |
| Return on equity | -44.1% |
| Period | 2025 |
Loading chart…
OpenFilings analyst
Our analyst
From latest 10-K · 2026-03-19
- Sbc Revenue High
- Operating Cf Burn
- Net Margin Sharply Negative
- Cash Conversion Weak
- Accumulated Deficit High
- Rd Intensity High
Red flags
- Sbc Revenue High — SBC/Revenue 136.1%
- Operating Cf Burn — Negative operating cash flow
- Net Margin Sharply Negative — Net margin -1115.3%
- Cash Conversion Weak — Cash conversion (CFO/Rev) -952.5%
- Accumulated Deficit High — Accumulated deficit / equity 288%
- Rd Intensity High — R&D/Revenue 884.1%
Upcoming earnings
9:00 PM UTC+1
Period
Sep 2026
Est. EPS
−$0.12
Est. revenue
618,180
Press & signals
- GlobeNewswire
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- GlobeNewswire
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- GlobeNewswire
Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update
The rest of this company's wire — with summaries and source links — is part of Pro.
See plansDocuments
FormReporting forFiledFlags